Ribonucleic Acid (RNA) Isolation Kit Market Global Report 2026

The ribonucleic acid (RNA) isolation kit market size has grown strongly in recent years. It will grow from $1.76 billion in 2025 to $1.93 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to growth in molecular biology research funding, expansion of genomics and transcriptomics studies, rising prevalence of infectious diseases requiring molecular diagnostics, increasing adoption of laboratory automation systems in research labs, development of column based and spin based extraction technologies.

The ribonucleic acid (RNA) isolation kit market size is expected to see strong growth in the next few years. It will grow to $2.72 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to integration of AI driven laboratory workflow optimization, increasing demand for precision medicine and personalized therapeutics, expansion of decentralized and point of care diagnostics, rising adoption of automated high throughput extraction platforms, growth in cell free and exosomal ribonucleic acid research applications. Major trends in the forecast period include automated magnetic bead based ribonucleic acid isolation for high efficiency sample processing, rise in ultra low input and single cell ribonucleic acid extraction workflows, growing adoption of RNase free and contamination resistant purification chemistries, expansion of viral ribonucleic acid isolation kits for infectious disease diagnostics, increasing demand for portable and rapid point of care ribonucleic acid extraction solutions.

The growing prevalence of infectious diseases is expected to propel the growth of the ribonucleic acid (RNA) isolation kit market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites, that spread through direct contact, contaminated surfaces, or environmental exposure. The prevalence of infectious diseases is increasing due to rapid urbanization, as densely populated urban settings promote greater person-to-person interaction and accelerate the transmission of communicable pathogens. Ribonucleic acid (RNA) isolation kits support infectious disease management by enabling the extraction and purification of high-quality RNA required for accurate molecular diagnostics and pathogen detection. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency, tuberculosis cases in the United States increased from 8,320 cases in 2022 to 9,615 cases in 2023, reflecting an increase of 1,295 cases. Therefore, the growing prevalence of infectious diseases is driving the growth of the ribonucleic acid (RNA) isolation kit market.

Major companies operating in the ribonucleic acid (RNA) isolation kit market are focusing on developing automated RNA extraction integration solutions, such as viral nucleic acid extraction kits, to improve nucleic acid purification efficiency, enhance diagnostic accuracy, reduce manual processing time, and support high-throughput molecular testing workflows. Viral nucleic acid extraction kits are laboratory solutions designed to isolate and purify viral DNA or RNA from biological samples for molecular analysis and diagnostic applications. For instance, in October 2025, Xpedite Diagnostics GmbH, a Germany-based provider of viral nucleic acid extraction kits and rapid nucleic acid extraction technologies, launched SwiftX Virus to improve rapid viral nucleic acid extraction efficiency, enhance molecular diagnostic accuracy, and support high-throughput testing for tropical and vector-borne diseases. The SwiftX Virus kit features a CE-IVD-certified one-step extraction workflow designed for the rapid isolation of both viral DNA and RNA from clinical samples.

In January 2024, MACHEREY-NAGEL, a Germany-based provider of scientific analysis solutions and manufacturer of ribonucleic acid (RNA) isolation kits, partnered with SARSTEDT to launch the NucleoSpin Dx RNA Blood kit, a CE-IVD-certified RNA isolation kit developed for the purification of RNA from human blood samples. Through this collaboration, MACHEREY-NAGEL aimed to strengthen its molecular diagnostics portfolio by integrating its expertise in nucleic acid isolation with SARSTEDT’s blood collection and RNA stabilization technologies, enabling reliable and standardized RNA-based diagnostic testing. SARSTEDT is a Germany-based provider of clinical blood collection and laboratory solutions.

Major companies operating in the ribonucleic acid (RNA) isolation kit market report are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Cytiva, Bio-Rad Laboratories Inc., QIAGEN N.V., Promega Corporation, Takara Bio Inc., MP Biomedicals LLC, Analytik Jena GmbH+Co. KG, MACHEREY-NAGEL GmbH & Co. KG, New England Biolabs Inc., Zymo Research Corporation, Bioneer Corporation, Shanghai Yeasen Biotechnology Co. Ltd., TIANGEN Biotech (Beijing) Co. Ltd., Geneaid Biotech Ltd., HiMedia Laboratories Pvt. Ltd., Norgen Biotek Corp., Vazyme Biotech Co. Ltd., Illumina Inc., Revvity Inc., Covaris LLC, LGC Biosearch Technologies.

North America was the dominating region in the ribonucleic acid (RNA) isolation kit market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) isolation kit market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid (RNA) isolation kit market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.